"Procedural History & Posture of Moore v. Regents: A Comprehensive Guide"
Moore v. Regents of the University of California, a landmark case in the realm of intellectual property law, has a procedural history and posture that have significantly shaped the landscape of patent law in the United States. This case, decided in 1984, centered around the question of whether a patent could be obtained on a live, human-made organism, specifically a genetically engineered bacterium.
Procedural History
The procedural history of Moore v. Regents began in 1974 when Ananda Chakrabarty, a scientist employed by the University of California, applied for a patent on a genetically engineered bacterium that could break down crude oil. The U.S. Patent and Trademark Office (PTO) initially rejected the application, arguing that live, human-made organisms were not patentable subject matter under 35 U.S.C. § 101, which outlines what is patentable.
The University of California, as Chakrabarty's employer, appealed the decision to the U.S. Court of Customs and Patent Appeals (CCPA), which affirmed the PTO's decision in 1978. The university then appealed to the U.S. Supreme Court, which agreed to hear the case in 1980. Oral arguments were held in 1981, and the Court issued its decision in 1984.
Patentable Subject Matter: The Key Issue
The central issue in Moore v. Regents was whether live, human-made organisms were patentable subject matter under 35 U.S.C. § 101. This section states that "whoever invents or discovers any new and useful process, machine, manufacture, or composition of matter, or any new and useful improvement thereof, may obtain a patent therefor, subject to the conditions and requirements of this title." The PTO and the lower courts had argued that live organisms were not patentable because they were products of nature, not human-made.
Supreme Court's Decision
The Supreme Court, in a 5-4 decision, reversed the CCPA's ruling and held that live, human-made organisms were patentable subject matter. The majority opinion, written by Justice Harry Blackmun, reasoned that the patent statute's use of the term "composition of matter" encompassed live organisms that were not naturally occurring. The Court also noted that Congress had amended the patent statute in 1952 to include the term "anything under the sun that is made by man" as patentable subject matter, which supported the patentability of live organisms.
The dissenting justices argued that the patent statute's use of the term "manufacture" did not include live organisms, and that the 1952 amendment did not change the patent statute's original purpose of promoting the progress of useful arts. They also expressed concern about the potential consequences of patenting life forms, such as restricting access to essential biological materials.
Posture of the Case and Its Impact
The posture of Moore v. Regents was that of a test case, challenging the longstanding PTO policy that live organisms were not patentable. The Supreme Court's decision in favor of patentability marked a significant shift in patent law, opening the door to the patenting of genetically engineered organisms and other forms of life.
The impact of Moore v. Regents has been profound. It has led to the issuance of thousands of patents on genetically engineered organisms, including patents on plants, animals, and even human genes. The case has also been cited in numerous other patent cases, both in the U.S. and abroad, as establishing the patentability of live, human-made organisms.
However, the decision has not been without controversy. Critics have raised concerns about the potential for patenting to restrict access to essential biological materials, to stifle innovation, and to raise ethical and social justice issues. These concerns have led to ongoing debates about the appropriate scope of patent protection for life forms and the need for further legal and policy reforms.
In conclusion, Moore v. Regents has played a pivotal role in shaping the patent law landscape in the United States. Its procedural history and posture have laid the groundwork for the patenting of live, human-made organisms, while also raising important questions about the appropriate scope of patent protection for life forms and the potential consequences of patenting in this area.